Your browser doesn't support javascript.
loading
A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer.
Limaye, Sewanti; Kumar, Prashant; Pragya, Ramya; Sambath, Janani; Patil, Darshana; Srinivasan, Ajay; Apurva, Sachin; Srivastava, Navin; Patil, Sanket; Patil, Revati; Datta, Vineet; Akolkar, Dadasaheb; Datar, Rajan.
Afiliação
  • Limaye S; Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India.
  • Kumar P; Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
  • Pragya R; Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India.
  • Sambath J; Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Patil D; Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India.
  • Srinivasan A; Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India.
  • Apurva S; Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Srivastava N; Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
  • Patil S; Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
  • Patil R; Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
  • Datta V; Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
  • Akolkar D; Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
  • Datar R; Datar Cancer Genetics Limited, Nasik, Maharashtra, India.
Oncotarget ; 11(46): 4358-4363, 2020 Nov 17.
Article em En | MEDLINE | ID: mdl-33245722
ABSTRACT
Ovarian cancer is common gynaecological malignancy and a leading cause of death among women. Despite the advances in treatment strategies, majority of patients present with recurrence after first- or second-line treatment. Targeted therapy that has proven to be effective in other advanced or metastatic solid tumors have also demonstrated its efficacy in ovarian cancer. Recent studies have shown that the androgen receptor (AR) signalling is involved in pathogenicity and progression of cancer. Current observations suggest AR could be a potential target in managing the disease. In this case report we present a patient with high grade serous ovarian cancer (HGSOC) with multiple relapses with excellent disease control on AR inhibition with bicalutamide.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article